Clinical trial · Interventional
The Effect of Curcumin for Treatment of Cancer Anorexia-Cachexia Syndrome in Patients With Stage III-IV of Head and Neck Cancer
A Double-blind, Placebo-controlled Randomized Trial Phase II Evaluating the Effect of Curcumin for Treatment of Cancer Anorexia-Cachexia Syndrome in Patients With Stage III-IV of Head and Neck Cancer
NCT04208334CI-TRIAL-00065074CurChexiacompletedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
A study of Curcumin to prevent cancer anorexia and cachexia Syndrom in locally advance and advance stage head and neck cancer (stage III, IV)
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer Cachexia | — | UNRESOLVED | — |
| Head and Neck Cancer | Malignant Head and Neck Neoplasm | ALIAS | 0.90 |
| Head and Neck Neoplasms | Head and Neck Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Curcumin | Dietary Supplement | — | UNRESOLVED |
| Placebo | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Curcumin
- description
- Curcumin 4000mg/day x 60 days
- interventionNames
- Dietary Supplement: Curcumin
- type
- PLACEBO_COMPARATOR
- label
- Placebo
- description
- Placebo x 60 days
- interventionNames
- Other: Placebo
Primary outcomes (1)
- measure
- Muscle mass
- timeFrame
- 60 days after intervention
- description
- We measure muscle mass by Bioelectrical Impedance Analysis (BIA)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Head and neck cancer stage III-IV * Cancer anorexia cachexia syndrome by 2011 Cancer cachexia an International Consensus * Enteral feeding with Nasogastric Tube or Gastrostomy * ECOG 0-2 * Normal Bone marrow, kidneys, and liver function * Normal function of enteral digestion and absorption Exclusion Criteria: * Pregnancy * History of allergy to Curcumin or herbal medicine * History of Herbal medicine used * History of Billiary of obstruction * History of Antiplatelete or anticoagulant.
References
Publications (26)
- BACKGROUNDArgiles JM, Busquets S, Stemmler B, Lopez-Soriano FJ. Cancer cachexia: understanding the molecular basis. Nat Rev Cancer. 2014 Nov;14(11):754-62. doi: 10.1038/nrc3829. Epub 2014 Oct 9. PMID 25291291
- BACKGROUNDPuigserver P, Rhee J, Lin J, Wu Z, Yoon JC, Zhang CY, Krauss S, Mootha VK, Lowell BB, Spiegelman BM. Cytokine stimulation of energy expenditure through p38 MAP kinase activation of PPARgamma coactivator-1. Mol Cell. 2001 Nov;8(5):971-82. doi: 10.1016/s1097-2765(01)00390-2. PMID 11741533
- BACKGROUNDMeriggi F. Cancer Cachexia: One Step Ahead. Rev Recent Clin Trials. 2015;10(3):246-50. doi: 10.2174/1574887110666150916141351. PMID 26435290
- BACKGROUNDArgiles JM, Lopez-Soriano FJ. The ubiquitin-dependent proteolytic pathway in skeletal muscle: its role in pathological states. Trends Pharmacol Sci. 1996 Jun;17(6):223-6. doi: 10.1016/0165-6147(96)10021-3. PMID 8763200
- BACKGROUNDGlass DJ. Signaling pathways perturbing muscle mass. Curr Opin Clin Nutr Metab Care. 2010 May;13(3):225-9. doi: 10.1097/mco.0b013e32833862df. PMID 20397318
- BACKGROUNDConstantinou C, Fontes de Oliveira CC, Mintzopoulos D, Busquets S, He J, Kesarwani M, Mindrinos M, Rahme LG, Argiles JM, Tzika AA. Nuclear magnetic resonance in conjunction with functional genomics suggests mitochondrial dysfunction in a murine model of cancer cachexia. Int J Mol Med. 2011 Jan;27(1):15-24. doi: 10.3892/ijmm.2010.557. Epub 2010 Nov 10. PMID 21069263
- BACKGROUNDArends J, Bachmann P, Baracos V, Barthelemy N, Bertz H, Bozzetti F, Fearon K, Hutterer E, Isenring E, Kaasa S, Krznaric Z, Laird B, Larsson M, Laviano A, Muhlebach S, Muscaritoli M, Oldervoll L, Ravasco P, Solheim T, Strasser F, de van der Schueren M, Preiser JC. ESPEN guidelines on nutrition in cancer patients. Clin Nutr. 2017 Feb;36(1):11-48. doi: 10.1016/j.clnu.2016.07.015. Epub 2016 Aug 6.